Should Hypertonic Saline Be Considered for the Treatment of Intracranial Hypertension? A Review of Current Evidence and Clinical Practices.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analysis
PubMed 39372110 · doi:10.13004/kjnt.2024.20.e35
What was done
This narrative review synthesized current evidence and clinical practices comparing hypertonic saline with mannitol for managing intracranial hypertension.
What was found
The abstract reports no numerical data, statistics, or effect sizes. Descriptively, both hypertonic saline and mannitol reduce intracranial pressure by establishing an osmotic gradient. Hypertonic saline is reported to better maintain cerebral perfusion by not inducing diuresis or significant blood pressure drops, does not cause rebound edema, and carries lower renal injury risk compared to mannitol. Noted risks of hypertonic saline include hypernatremia, hyperchloremia, and fluid overload.
Why it matters
Hypertonic saline serves as an alternative osmolar agent that preserves hemodynamics and cerebral perfusion pressure without inducing the osmotic diuresis seen with mannitol.
Limits
This is a narrative review lacking systematic search methodology, meta-analysis, or quality appraisal. The abstract provides no quantitative metrics, patient sample sizes, specific etiologies of intracranial hypertension, or standardized dosing protocols.
Cited by
- context Sodium supplementation in injured patients helps mitigate swelling of the injured tissue.